Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00621049 | Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC | completed | Phase 2 | 112 | SCRI Development Innovations, LLCOTHER | 1 | Jun 8, 2015 | clinicaltrials |
| NCT01562015 | A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)(CHIARA) | completed | Phase 2 | 12 | Synta Pharmaceuticals Corp.INDUSTRY | 2 | May 20, 2015 |
| NCT00892710 | Trial of Poor Performance Status Patients (ToPPS)(ToPPS) | completed | Phase 2 | 172 | SCRI Development Innovations, LLCOTHER | 1 | May 15, 2015 | clinicaltrials |
| NCT02175381 | Carboplatin Plus Gemcitabine for Elderly Patients With Stage IV NSCLC | completed | Phase 1 / Phase 2 | 69 | Hellenic Oncology Research GroupOTHER | 1 | May 15, 2015 | clinicaltrials |
| NCT00316186 | First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin | completed | Phase 2 | 33 | GlaxoSmithKlineINDUSTRY | 2 | May 7, 2015 | clinicaltrials |
| NCT00743379 | Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 71 | Threshold PharmaceuticalsINDUSTRY | 1 | May 7, 2015 | clinicaltrials |
| NCT00470054 | Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | May 5, 2015 | clinicaltrials |
| NCT00521144 | Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | May 5, 2015 | clinicaltrials |
| NCT00716456 | Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib | completed | Phase 1 / Phase 2 | 21 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 30, 2015 | clinicaltrials |
| NCT01500720 | Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer | completed | Phase 2 | 179 | SanofiINDUSTRY | 16 | Apr 13, 2015 | clinicaltrials |
| NCT02154399 | EF5 in Measuring Tumor Hypoxia in Patients With Stage I-III Non-Small Cell Lung Cancer | completed | Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Apr 13, 2015 | clinicaltrials |
| NCT01039948 | A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 203 | AVEO Pharmaceuticals, Inc.INDUSTRY | 7 | Apr 8, 2015 | clinicaltrials |
| NCT00078455 | Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma | completed | Phase 2 | — | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 5, 2015 | clinicaltrials |
| NCT00511485 | Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03) | completed | Phase 2 | 43 | EndocyteINDUSTRY | 0 | Feb 27, 2015 | clinicaltrials |
| NCT00531934 | A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer. | completed | Phase 2 | 147 | Hoffmann-La RocheINDUSTRY | 1 | Feb 25, 2015 | clinicaltrials |
| NCT00384826 | Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma | completed | Phase 2 | 133 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Feb 16, 2015 | clinicaltrials |
| NCT00759824 | A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide | completed | Phase 2 | 64 | European Lung Cancer Working PartyOTHER | 1 | Feb 12, 2015 | clinicaltrials |
| NCT01578668 | Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases | completed | Phase 2 | 69 | Guangzhou Medical UniversityOTHER | 1 | Jan 26, 2015 | clinicaltrials |
| NCT00711594 | LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib | completed | Phase 2 | 74 | Boehringer IngelheimINDUSTRY | 1 | Jan 15, 2015 | clinicaltrials |
| NCT01998919 | A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer. | completed | Phase 2 | 154 | Hoffmann-La RocheINDUSTRY | 8 | Jan 13, 2015 | clinicaltrials |
| NCT00400829 | E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2015 | clinicaltrials |
| NCT02323737 | Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung Cancer | completed | Phase 2 | 62 | Chinese Academy of Medical SciencesOTHER | 1 | Dec 30, 2014 | clinicaltrials |
| NCT00735696 | A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer | completed | Phase 2 | 41 | Eli Lilly and CompanyINDUSTRY | 2 | Dec 29, 2014 | clinicaltrials |
| NCT02013206 | A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to Chemotherapy | completed | Phase 2 | 52 | Hoffmann-La RocheINDUSTRY | 6 | Dec 19, 2014 | clinicaltrials |
| NCT00160043 | Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer. | completed | Phase 2 | 112 | BayerINDUSTRY | 2 | Dec 16, 2014 | clinicaltrials |
| NCT00160069 | Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer | completed | Phase 2 | 128 | BayerINDUSTRY | 1 | Dec 4, 2014 | clinicaltrials |
| NCT01498562 | Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer(DATE) | completed | Phase 2 | 160 | Yonsei UniversityOTHER | 1 | Dec 2, 2014 | clinicaltrials |
| NCT00240097 | Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC) | completed | Phase 2 | 30 | University of Alabama at BirminghamOTHER | 1 | Nov 27, 2014 | clinicaltrials |
| NCT00800202 | A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis | completed | Phase 2 | 91 | Hoffmann-La RocheINDUSTRY | 1 | Nov 19, 2014 | clinicaltrials |
| NCT01427946 | Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 47 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Nov 13, 2014 | clinicaltrials |
| NCT00531960 | A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer. | completed | Phase 2 | 124 | Hoffmann-La RocheINDUSTRY | 13 | Nov 11, 2014 | clinicaltrials |
| NCT00799240 | MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer(IMPACT) | completed | Phase 2 | 27 | University of KansasOTHER | 1 | Nov 7, 2014 | clinicaltrials |
| NCT01593995 | EGF Ointment for Erlotinib Skin Lesion | completed | Phase 2 | 52 | Dong-A University HospitalOTHER | 1 | Nov 4, 2014 | clinicaltrials |
| NCT00481078 | Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer | completed | Phase 2 | 94 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2014 | clinicaltrials |
| NCT01844791 | An Exploratory Study of OCZ103-OS in Combination With Standard of Care in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients | completed | Phase 2 | 25 | Oncozyme Pharma Inc.INDUSTRY | 1 | Oct 21, 2014 | clinicaltrials |
| NCT00201825 | A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients | completed | Phase 2 | 29 | Tony Bekaii-SaabOTHER | 1 | Oct 6, 2014 | clinicaltrials |
| NCT01473563 | A Study of Home Administration of Pemetrexed as Maintenance Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 52 | Eli Lilly and CompanyINDUSTRY | 2 | Oct 6, 2014 | clinicaltrials |
| NCT00245063 | AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer | completed | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Oct 2, 2014 | clinicaltrials |
| NCT00986674 | Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 140 | National Cancer Institute (NCI)NIH | 1 | Sep 26, 2014 | clinicaltrials |
| NCT00700180 | A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer. | completed | Phase 2 | 303 | Hoffmann-La RocheINDUSTRY | 16 | Sep 25, 2014 | clinicaltrials |
| NCT01459185 | A Feasibility Study of Oral Adjuvant Chemotherapy With S-1 | completed | Phase 2 | 55 | Tomoshi TsuchiyaOTHER | 1 | Sep 25, 2014 | clinicaltrials |
| NCT01031225 | A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 113 | Synta Pharmaceuticals Corp.INDUSTRY | 1 | Sep 19, 2014 | clinicaltrials |
| NCT00912392 | Etoposide-Carboplatin Alone or With Endostar for Extensive Disease Small Cell Lung Cancer (ED-SCLC) | completed | Phase 2 | 138 | Shandong Simcere-Medgenn Bio-pharmaceutical Co., LtdINDUSTRY | 1 | Sep 3, 2014 | clinicaltrials |
| NCT00118144 | Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2014 | clinicaltrials |
| NCT00372788 | AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen | completed | Phase 2 | 88 | AstraZenecaINDUSTRY | 3 | Aug 13, 2014 | clinicaltrials |
| NCT01236716 | Nab-Paclitaxel Treatment in Advanced Squamous Cell Carcinoma of Lung(C-TONG1002) | completed | Phase 2 | 126 | Chinese Society of Lung CancerOTHER | 1 | Aug 6, 2014 | clinicaltrials |
| NCT00193921 | Chemoradiotherapy in Patients With Localised Lung Cancer | completed | Phase 2 | 82 | Trans Tasman Radiation Oncology GroupOTHER | 1 | Aug 4, 2014 | clinicaltrials |
| NCT00796549 | BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients | completed | Phase 2 | 70 | Boehringer IngelheimINDUSTRY | 1 | Jul 22, 2014 | clinicaltrials |
| NCT00415818 | Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 148 | TransgeneINDUSTRY | 4 | Jul 16, 2014 | clinicaltrials |
| NCT01362296 | An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer | completed | Phase 2 | 134 | GlaxoSmithKlineINDUSTRY | 8 | Jul 11, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Jun 8, 2015source: clinicaltrials